Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Maximilian Stahl, Brian Ball et al.|Leukemia|2024Cited by 30
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AMLJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|Blood Advances|2024Cited by 12
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort studyJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|American Journal of Hematology|2024Cited by 9
What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort StudyShai Shimony, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 2
The Prognostic and Predictive Value of <i>RUNX1</i> Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort StudyRebecca P. Bystrom, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 0